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Abstract
Trauma is the leading cause of death for people ages 1-44, with blood loss comprising 60-70% of
mortality in the absence of lethal CNS or cardiac injury. Immediate intervention is critical to
improving chances of survival. While there are several products to control bleeding for external
and compressible wounds including pressure dressings, tourniquets or topical materials (e.g.
QuikClot, HemCon), there are no products that can be administered in the field for internal
bleeding. There is a tremendous unmet need for a hemostatic agent to address internal bleeding in
the field.
We have developed hemostatic nanoparticles (GRGDS-NPs) that reduce bleeding times by ~50%
in a rat femoral artery injury model. Here, we investigated their impact on survival following
administration in a lethal liver resection injury in rats. Administration of these hemostatic
nanoparticles reduced blood loss following the liver injury and dramatically and significantly
increased 1-hour survival from 40 and 47% in controls (inactive nanoparticles and saline,
respectively) to 80%. Furthermore, we saw no complications following administration of these
nanoparticles. We further characterized the nanoparticles’ effect on clotting time (CT) and
maximum clot firmness (MCF) using rotational thromboelastometry (ROTEM), a clinical
measurement of whole-blood coagulation. Clotting time is significantly reduced, with no change
in MCF. Administration of these hemostatic nanoparticles after massive trauma may help staunch
bleeding and improve survival in the critical window following injury, and this could
fundamentally change trauma care.
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Trauma is the leading cause of death for individuals between ages 1-44.1 More than one-
third of patients die before reaching the hospital.1 In military trauma, outcomes are even
worse.2 Injuries are often more severe and can have the additional complication of a
prolonged prehospital phase, defined as the time between injury and admission to the
hospital.2, 3 Hemorrhage accounts for 50% of penetrating battlefield trauma mortality, and
80% of these deaths are secondary to injury in the torso, where conventional methods for
hemostasis, such as pressure dressings, tourniquets, QuikClot, or HemCon are impossible
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(noncompressible injuries).2, 4-6 The way Clifford5 poses the challenge is that while civilian
blunt trauma patients may have a “golden hour”, military personnel with penetrating trauma
may only have a “platinum 5 minutes”, during which, catastrophic hemorrhage may occur.
This places a large emphasis on the first-response medics to stabilize patients prior to
transportation to a hospital. For civilian and non-civilian application, there is a tremendous
unmet need for a field-administrable hemostatic agent to address internal hemorrhage.3
There is a dearth of tools to address internal bleeding. Methods that have been pursued
include blood and blood product transfusions, and treatment with clotting factors such as
recombinant factor VIIa (RFVIIa).7 Resuscitative strategies with blood components such as
fibrinogen or platelets are limited by their necessity for donor sources,
immunocompatibility, need for refrigeration and risk of loss of activity during storage or
preservation methods.7 These complications limit their use to hospital settings. The
administration of recombinant factor VIIa intravenously to reduce bleeding after acute
trauma has been a topic of debate.5, 8-10 Several studies have shown that perioperative
administration of RFVIIa reduces the volume of blood transfusion. However, it is unclear
whether the benefit is large enough to have any associated effect on mortality after
hemorrhagic trauma.11, 12 Its potential use in the prehospital phase is further diminished due
to its high cost, potential for adverse effects, and necessity to be stored at 2-8 °C.8, 13
Intravenous administration of hemostatic nanoparticles that target activated platelets have
been investigated by a number of groups with some promise and a range of challenges.14-16
RGD conjugated red blood cells (RBCs) called thromboerythrocytes showed promise in
vitro but did not significantly reduce prolonged bleeding times in thrombocytopenic
primates.14, 17 Furthermore, the use of allogenic RBCs may produce an immune response in
the recipient that further impedes clinical translation.18 Fibrinogen-coated albumin
microparticles (3.5-4.5 Im diameter), “Synthocytes,” 19 and liposomes (220 nm diameter)
carrying the fibrinogen γ chain dodecapeptide (HHLGGAKQAGDV)20, 21 showed success
in bleeding models in thrombocytopenic rabbits. However, Synthocytes were ineffective in
treating bleeding in normal rabbits19 and may be hindered by their large size; Merkel et al.
has shown that particles, especially those that are large and not mechanically compliant, are
prone to aggregation in the lungs, which may increase the propensity for pulmonary
complications.22, 23 The liposomes from Okamura et al. 20, 21 do not appear to have yet been
studied in non-thrombocytopenic animals.
From this work, several things are clear. First, large particles and those including potentially
immunogenic materials (i.e. biologically derived materials) carry additional and possibly
unnecessary risks. Second, what works in vitro may not translate to in vivo conditions, or to
the general (non-thrombocytopenic) trauma population. Because the coagulation system is
so complex, multiple bleeding models (and species) with functionally-directed outcomes, in
concert with in vitro studies, are required to fully evaluate a potential therapy, as has been
recognized by the FDA in a set of published guidelines for platelet substitutes.24
Prothrombotic potential, immunogenicity, and toxicity due to additives are among the safety
criteria, and efficacy criteria is based on a battery of in vivo and in vitro tests.
We have developed novel hemostatic nanoparticles (GRGDS-NPs) that can be administered
intravenously to reduce bleeding times by ~ 50% in a model of rat femoral artery injury,
performing better than saline or RFVIIa controls.25 These nanoparticles are made of
biodegradable polymers, reducing the risk of long-term immunological and inflammatory
reactions. The salient features of these nanoparticles include a 400 nm core made of
biodegradable block copolymer of poly(lactic-co-glycolic acid) (PLGA) and poly-ε-L-
lysine(PLL) with poly(ethylene glycol) (PEG) arms terminated with arginine-glycine-
aspardic acid (GRGDS)-based targeting ligands (Figure 1a). GRADSP ligands are used as a
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scrambled peptide to control for nonspecific actions of the particles (Scrambled-NPs). For
research purposes, the nanoparticles have been loaded with coumarin-6, a fluorescent dye
that allows us to track their Biodistribution.25
In this study, we investigated the impact of intravenous delivery of the GRGDS-NPs on
blood loss and survival in a clinically relevant model of blunt trauma. We sought to evaluate
our treatment in vivo and in vitro to help elucidate efficacy and mechanism. We investigated
the nanoparticles in a lethal liver injury model to determine 1) whether the nanoparticles had
an effect in a complex solid organ injury, 2) if that effect produced any functional impact on
blood loss and mortality outcomes, and 3) to investigate the effects of the nanoparticles on
clotting time and clot firmness parameters using rotational thromboelastometry (ROTEM),
to better understand the mechanism by which the nanoparticles augment hemostasis. The
data from these studies is a critical step in determining the clinical potential of these
particles and gaining insight into nanomedicine more broadly.
MATERIALS AND METHODS
Materials
PLGA (Resomer 503H) was purchased from Evonik Industries. Poly-L-lysine and PEG
(~4600 Da MW) were purchased from Sigma Aldrich. All reagents were ACS grade and
were purchased from Fisher Scientific.
Particle synthesis
A PLGA-PLL-PEG triblock polymer was synthesized using stepwise conjugation reactions,
starting with PLGA (Resomer 503H) and poly(ε-cbz-L-lysine) (PLL-cbz) PLL with
carbobenzoxy-protected side amine side groups (Sigma P4510) as previously described.25,
26 This conjugation reaction was confirmed using UV-Vis to check for a signature triple
peak corresponding to the cbz groups. After deprotecting the PLGA-PLL-cbz with HBr, the
free amines on the PLL-NH3 were reacted with CDI-activated PEG in a 5:1 molar excess.27
The conjugated triblock copolymer PLGA-PLL-PEG (with CDI activated PEG endgroups)
was dissolved to a concentration of 20 mg/ml in acetonitrile containing coumarin-6 (C6), a
fluorescent dye is used to track the nanoparticles after injection (loaded at 1% w/w). This
dye has been shown previously to release less than 0.5% of the initial loading by 24 h and
less than 1.5% by 7 days.25 This solution was added dropwise to a volume of stirring PBS,
twice that of the acetonitrile.28 Precipitated nanoparticles form as the water-miscible solvent
is displaced. The nanoparticles were then conjugated with GRGDS or the conservatively
substituted GRADSP peptide and stir-hardened for 3 hours in a single step. Nanoparticles
were then collected using the coacervate precipitation method described below.
Coacervate precipitation and resuspension
The method for nanoparticle collection was adapted from D’Addio et al.29 One mass
equivalent of dry poly(acrylic acid) (pAA) (Sigma, MW = 1,800) was added to the stirring
particle suspension. 1% w/v pAA was then added to the stirring suspension until
flocculation occurred, approximately 10 ml. After 5 minutes, the flocculated nanoparticles
were collected by centrifugation and rinsed 3 times. Nanoparticles were resuspended to
approximately 10 mg/ml with deionized water, snap-frozen in liquid nitrogen and
lyophilized for 3 days. Nanoparticles were resuspended to a concentration of 20 mg/ml in 1x
PBS and briefly sonicated (VCX-130, Sonics & Materials, Inc.).
Characterization
Nanoparticles were characterized for size distribution, size polydispersity and zeta potential
(in 1 mM KCl buffer) using dynamic light scattering (90Plus, Brookhaven Instruments
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Corporation) and scanning electron microscopy (Hitachi S4500). DLS data was represented
as the effective diameter as calculated by the 90Plus software. SEM images were analyzed
in ImageJ software. Successful conjugation of PLL, PEG and peptide ligands was confirmed
using UV-spectroscopy, 1H-NMR and amino acid analysis HPLC (BioRad, Varian and
Shimadzu respectively). 1H-NMR is performed with chloroform for analyzing the triblock
structure and deuterated water to verify the PEG coronal shell.30 Amino acid analysis was
performed by W.M. Keck Foundation Biotechnology Resource Laboratory (New Haven,
CT).
In vitro coagulation assay (ROTEM)
Coagulation assays, using Sprague Dawley rat blood, were performed using the ROTEM’s
NATEM test in the presence of either saline, GRGDS-NPs, or scrambled GRADSP-NPs.
The blood collection method (cardiac puncture) was rigidly followed to minimize variability
in the highly sensitive NATEM test. A 5 ml syringe is loaded with 0.5 ml of 3.8% disodium
citrate prepared in 1x PBS. Rats were anesthetized with a ketamine:xylazine rodent cocktail
(90:10 mg/kg, i.p.). 4.5 ml of blood is collected to mix with the anticoagulant solution at a
1:9 ratio (soln:blood). For a given run, the cup of blood consisted of: 300 Il citrated blood,
20 Il starTEM reagent (0.2 mM calcium chloride), 20 Il nanoparticles (1.25 or 2.5 mg/ml),
totaling a 340 Il sample. To account for time dependency on coagulation tests, a block of 4
NATEM tests were run simultaneously on a single ~1.2 cc aliquot of blood, where saline
was always included as one of the four tests. The raw data was analyzed using a generalized
linear model, with run time as blocks and with Tukey comparisons between groups. The
main outcomes we considered include the standard ROTEM parameters clotting time (CT),
clot formation time (CFT), the sum of the two (CT+CFT), and maximum clot firmness
(MCF). CT is defined as the time from the start of the assay until the initial clotting is
detected (thickness = 2mm). CFT is defined as the time between the initial clot (thickness =
2mm) until a clot thickness of 20 mm is detected. MCF is defined as the maximum thickness
(in mm) that a clot reaches during the duration of the test.
In vivo liver injury model
In order to assess the efficacy of the nanoparticles to augment survival in a lethal injury
model, a liver injury model was adapted from Ryan et al. 31 and Holcomb et al. 32 and is
described below. The injury model was approved and undertaken according to the guidelines
set by Case Western Reserve University’s institutional animal care and use committee. The
main outcomes recorded for this study include survival at 1 hour and blood loss as measured
with pre-weighed gauze.
Surgical procedure
Sprague Dawley rats (225-275 g, Charles River) were anesthetized with intraperitoneal
ketamine:xylazine (90:10 mg/kg, respectively). After 10 minutes, they were shaved and
placed in a supine position on a heatpad. The abdomen was accessed and the medial lobe of
the liver was marked with an arch radius 1.3 cm from the suprahepatic vena cava using a
handheld cautery device. Once marked, the tail vein was exposed, and catheterized with a
saline-flushed 24G x 3/4″ Excel Safelet Catheter. The medial liver lobe was then resected
along the marked lines, the abdomen was closed with wound clips, and 0.5 cc bolus
treatment solution was immediately administered followed by 0.2 cc saline flush to clear the
catheter dead-volume.
The rats were allowed to bleed for 1 hour or until death, as confirmed by lack of both
breathing and a palpable heartbeat. Before measuring blood loss, all rats were injected with
a lethal dose of sodium pentobarbital (i.v.). The abdomen was then reopened and blood
collected with pre-weighed gauze. The clot adherent to the liver was collected last as this
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usually caused additional bleeding to occur. The resected liver was weighed and fixed in
10% buffered formalin solution. Remaining liver, kidney, spleen, lungs and adherent clot
were harvested and similarly preserved in 10% buffered formalin.
Procedure and statistics
Treatments included no injection (n=3), saline (n=17), scrambled-NPs (n=15), and
hemostatic GRGDS-NPs (n=20). Particle treatments were resuspended to 20 mg/ml in PBS.
The surgeon was blinded to the treatments and all blood loss measurements and death were
independently recorded by a second person also blinded to the treatment. The no injection
group (n=3) was included as a reference, but was not included in the statistics. ANOVA with
Tukey comparisons was used to analyze blood loss data (Minitab). Survival was analyzed
with a binomial logistic regression with chi-squared tests between odds-ratios (SAS). A
power analysis based on preliminary studies suggested an n=15 per group for significance
for survival data (alpha = 0.05, beta = 0.2, odds ratio = 3).
Biodistribution
Liver, kidney, spleen, lung and adherent clots were harvested and lyophilized for the
biodistribution assay. The dry weight of the whole organ was recorded and 100-200 mg of
dry tissue was homogenized (Precellys 24) and incubated overnight in acetonitrile at 37 °C.
This dissolved any nanoparticles present in the tissue and left the C6 in the organic solvent
solution. Tubes were then centrifuged at 15,000 g for 10 minutes to remove solid matter and
supernatant was tested on the HPLC. Mobile phase was 80% acetonitrile, and 20% aqueous
(8% acetic acid). Stationary phase was a Waters Symmetry C18 Column, 100Å, 5 Um, 3.9
mm X 150 mm with fluorescence detection (450/490 nm ex/em). Based on the known C6
loading and injection volume of particles, data is represented as percent (%) of particles
injected.
Imaging injury surface and adherent clots
Resected portions of the liver were rinsed and placed directly on a high-resolution (1200
dpi) flatbed scanner (Cannon CanoScan LiDE 700F) to image the surface of the injury.
Adherent clots, still attached to livers were fixed in 10% formalin, soaked overnight in
sucrose, frozen and cryosectioned to 20-micron thickness. Sections were then stained with
VectaShield DAPI to stain hepatocyte nuclei and imaged with an inverted fluorescence
microscope (Zeiss Axio Observer.Z1). Several clots per group were fixed in 10% formalin,
and dehydrated in serial steps with ethanol to prepare them for imaging with a scanning
electron microscope (SEM). These were then dried overnight in anhydrous
hexamethyldisilazane and sputter coated. Samples were mounted and imaged with a Hitachi
S4500 field emission SEM at 5kx magnification.
RESULTS
Particle synthesis and characterization
The PLGA-PLL-PEG triblock polymer is synthesized using stepwise conjugation reactions,
starting with PLGA (Resomer 503H) and poly(ε-cbz-L-lysine) PLL with carbobenzoxy-
protected side amine side groups following Bertram et al. 25, 26, 33 Conjugation efficiency
for this step is approximately ~30-40% molar ratio PLL:PLGA, as determined by UV-vis.
After deprotection of side groups, the free amines on the PLL are reacted with CDI-activated
PEG. This PEG creates a hydrophilic shell around the nanoparticles that allow them to have
a longer residence time in blood circulation 30 (Figure 1a). 1H-NMR in deuterated
chloroform and deuterated water is performed to verify the expected surface-pegylated
structure (Figure 1c). Peaks a, b, and d confirm the composition of PLGA (50:50), and peak
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c confirms the presence of PEG. From this spectrum, percent pegylation is calculated to be
1:10 (PEG:PLGA) molar ratio. In deuterated water, the PEG peak becomes much larger in
relation to the other peaks and confirms the PEG-coronal structure of the nanoparticles in an
aqueous environment. This is further verified by a neutral zeta potential result when making
nanoparticles consisting of the PLGA-PLL-PEG triblock polymer, suggesting the positively
charged PLL is shielded by PEG. However, once incorporated, the surface-conjugated
peptides do impart a slightly negative charge: −27.84 mV +/− 2.76 mV for the GRGDS-NPs
and −13.47 mV +/− 3.64 mV for the scrambled-NPs. The size and distribution of the
nanoparticles cores (by SEM) and in the aqueous environment (by DLS) is homogenously
distributed around 400 nm and 420 nm respectively (Table 1). The increase in size from
SEM to DLS can be accounted for by the hydration shell, created by the PEG arms. There
appears to be a slight increase in size as a result of C6 loading (approximately 5-10%), with
no significant change in size depending on the GRGDS or GRADSP peptide conjugated.
In vivo injury model development
Following injury of the medial lobe (Figure 1d), rats were administered either saline,
scrambled (GRADSP), or hemostatic (GRGDS-conjugated) nanoparticles. Saline is used as
the baseline control because the administration of fluids can impact bleeding.34 Based on
our preliminary results, we found that resected liver mass and body mass were correlated
with bleeding outcomes, and similar to Holcomb et al.,32 we chose to strictly adhere to
inclusion criteria for rat body mass (225-275 g) and liver resection (0.8-1.2% of body mass)
(Figure 2c-d). At the conclusion of the study, we found that body mass was no longer
correlated with our bleeding outcomes and we assume our body mass inclusion criteria was
a tight enough range to limit its effects on blood loss in our study. However, resected liver
mass was still significantly correlated with blood loss (p=0.0004), meaning 0.8%-1.2% liver
resection (or approximately +/− 0.5 g wet tissue weight), was enough to still significantly
affect blood loss outcomes (i.e. a larger resection led to more bleeding, and a smaller
resection led to less bleeding). We therefore included resected liver mass as a covariate in
our ANOVA analysis to account for its impact. While there is a trend toward reduction in
blood loss with the GRGDS-NP group, the impact of treatment on blood loss was still not
statistically significant (p=0.113).
1-Hour survival
One of the most critical parts of this work was to determine whether administration of the
nanoparticles led to improved survival following blunt trauma injury. Administration of the
hemostatic, GRGDS nanoparticles significantly improves survival following the lethal liver
injury. Specifically, the GRGDS-NPs increases the odds of survival to 80% (Figure 2a-b).
This is compared to 47% in the saline group (p=0.040, odds ratio (OR)=4.5, 95% CI
1.1-19.2) and 40% in the scrambled-NP group (p=0.019, OR=6, 95% CI 1.3-27.0).
Administering the GRGDS-NPs almost doubles the chances of survival from this lethal
injury.
Blood loss
We know from our previous work 25 that the GRGDS-NPs reduce bleeding. In this work, we
measured blood loss through the weight change in gauze used to absorb the blood in the
body cavity at the end of the experiment. This method provides data on blood loss but lacks
the fine resolution permitted in the previous study. Measuring total blood loss in this model
is complicated by the impact of survival time. The rate of blood loss may be a better
indicator of survival for this model, but since the injury model is maintained in the small,
closed cavity of rats, blood loss could not be dynamically measured. Nonetheless, we saw a
trend in blood loss that correlates with survival with the GRGDS-NPs exhibiting the least
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blood loss. This trend towards reduction in blood loss is not statistically significant
(p=0.0552), but it suggests that the GRGDS-NPs are improving survival through mitigation
of bleeding (Figure 2e). There also appears to be a critical threshold around 35% blood
volume loss, above which there is rapidly increasing proportion of mortality (Figure 2f).
Imaging injury surface
To help validate that our GRGDS-NPs are targeting the injury site, and accumulating within
the clot, we imaged the injury surface using several modalities including fluorescent
microscopy and SEM. Nanoparticles loaded with the fluorescent compound coumarin-6
(C6) are found within the injury surface, integrated with the clot (Figure 3). The injury
surface is also characterized using a flatbed scanner to help depict the nature of the injury.
From visual observation of the injury during model development, it is apparent that the
majority of bleeding occurs through the 2-4 major blood vessels that are transected in the
medial lobe injury.
Biodistribution
For the GRGDS-NPs, 31.1% of the injected dose is found in the clot versus only 6.8% for
the scrambled-NP group. Total recovery of the nanoparticles between the clot and organs
tested was 53.7% and 29.6% for the GRGDS-NPs and scrambled-NP groups, respectively;
the unrecovered proportion is most likely located in the shed blood, not actively
participating in the clot, or remaining in plasma circulation. There was a relatively large
percentage of nanoparticles found in the lungs for each group, 20.8% and 20.6% (GRGDS
and Scrambled, respectively), and a small percentage found in the other organs tested
(<2%).
In vitro coagulation model
A dosing study was performed using rotational thromboelastometry (ROTEM), with citrated
rat blood. In this assay, a 20 Il volume of PBS containing a varying concentration of
nanoparticles was added to a 300 Il volume of blood immediately before starting the assay.
Clotting time (CT) and clot formation time (CFT) were recorded, corresponding to the time
it took to form a 2 mm clot size and 20 mm clot size respectively. Here we considered the
total time to form a 20 mm clot (CT+CFT). In addition to saline, concentrations of
nanoparticles tested included 0.625, 1.25, 2.5, 5.0, and 20 mg/ml for GRGDS and scrambled
nanoparticle groups. In all concentrations tested in the scrambled group, the CT+CFT
increased and the MCF decreased compared to saline. In GRGDS-NP 1.25 and 2.5 mg/ml
concentrations, MCF increased. Similarly, the CT+CFT is decreased in 1.25 mg/ml, and 5.0
mg/ml groups, but was increased otherwise. This is indicative of a clot forming faster and
thicker when treated with the nanoparticles at an optimal dose, approximately 73.5-294 Ig/
ml in the blood or a 5.2-20 mg/kg dose for a 250 g male rat, assuming 68.6 ml/kg blood
volume.35
We then further investigated 1.25 and 2.5 mg/ml concentrations as these had the most
favorable effects on clotting parameters. We used a randomized block experimental method,
using saline as the control for each test-block. The 2.5 mg/ml GRGDS-NP dose significantly
reduced CT+CFT compared to saline controls (p=0.0437) and had a trend toward increasing
MCF although the difference was not significant (n=3 rats, with triplicate measurements at
each treatment-dose level). The 2.5 mg/ml GRGDS-NP dose significantly reduced CT+CFT
compared to saline controls (p=0.0437) and had a trend toward increasing MCF although not
statistically significant. Interestingly, the scrambled-NP groups also appeared to reduce CT
+CFT and increase MCF, but the differences were not significantly different from either
saline or GRGDS treatments (Figure 5).
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Administration of hemostatic nanoparticles increased 1-hour survival
Early intervention is critical to improve chances of survival following trauma, and we see
the effects of early intervention in this work. For all groups tested, there was a window of 20
minutes, after which, the odds of survival improved, as well as a critical blood volume loss
of approximately 35% blood volume, below which 95% of rats survived.
Nearly twice as many rats survive one hour with administration of the hemostatic
nanoparticles compared to controls. This result is statistically significant and clinically
promising. We have seen previously that these hemostatic nanoparticles are stable at room
temperature and reduce bleeding in a controlled injury model, but one of the major questions
was whether this reduction in blood loss would impact survival in lethal trauma models of
bleeding. The liver injury model is one of the most reproducible and comparable in the field.
31, 32, 36 Seeing an almost two fold increase in survival with the GRGDS-NPs confirms
that they not only reduce bleeding but do so at a level that impacts survival in the critical
prehospital window.
There is a 4.5-fold higher amount of GRGDS-NPs found in the adherent liver clot compared
to the scrambled-NP group, with very small quantities of nanoparticles found in the kidney,
spleen and uninjured liver, confirming their injury-targeting capability. Nearly 20% of
injected nanoparticles have been found in the lungs regardless of the treatment group. While
some basal level of nanoparticles in the lungs is expected due to the pulmonary perfusion
still present in the organ at the time of collection, previous studies in naïve rats estimate this
to account for only 5-10% of the injected dose.25 These findings may indicate that the
nanoparticles could be accumulating in thromboemboli in the lungs, concomitant with the
massive hemorrhagic nature of this injury model.37 However, it is of particular interest to
note that survival does not appear to be deleteriously impacted—rather the opposite. It
therefore reasons to argue that these thrombi are also present in the saline control, and may
be present as microemboli that may not have any clinical presentation.37, 38 Future studies
may be aimed at assessing the risk of particle aggregation in the lungs and determining what
functional impacts they may have, for example, by monitoring lung perfusion, tissue
oxygenation, or blood gas levels. The ease of intravenous administration of these
nanoparticles, coupled with their effective injury-targeting without deleterious functional
outcomes bodes well for translation of this therapy to the clinic.
We observed a trend toward reduction in blood loss with the functionalized treatment versus
controls. However, the methods for blood collection in trauma models in rats are limited,
and the sensitivity is modest at best. Therefore, it is not surprising that we were not able to
resolve the differences between the groups in this area to statistical significance. A power
analysis to determine the number of animals needed to see differences suggests that an
unethically large number of animals would be needed. While this model is not acutely
sensitive to differences in blood loss, the trend regarding blood loss correlates well with the
survival outcomes, the key point of this study.
One of the questions that plays an important role in the safety and efficacy of a technology
like this is the mechanism by which the nanoparticles reduce bleeding. We successfully
titrated the optimal whole-blood dosing of the nanoparticles using this in vitro model by
using rotational thromboelastometry (ROTEM). This confirmed that their effect on clotting
times was dose dependent and the optimal dose tested was the 2.5 mg/ml GRGDS-NP
group, corresponding to a blood concentration of 147 ug/ml (particle mass/blood volume).
Interestingly, the scrambled-NPs have a trend toward an in vivo increase in blood loss and a
decrease in survival compared to saline. In conjunction with our preliminary ROTEM data
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that suggests the scrambled particles may actually decrease MCF at higher concentrations, it
is possible that the scrambled-NPs are destabilizing the clot and explain our in vivo findings.
However, on the other hand, the GRGDS-NPs reduce clotting time and tend to increase clot
firmness, so we hypothesize the mechanism for increased survival is more rapid clot
formation and increase in clot strength, leading to the reduction in blood loss and increase in
survival.
CONCLUSION
Trauma is the leading cause of death among young people, and blood loss plays a major role
in those deaths.1 We have developed a hemostatic nanoparticle that can be administered
easily following injury that reduces bleeding and significantly increases survival following a
blunt trauma injury. This is a clinically relevant result as this suggests that this treatment
could be used in the field to expand the window of treatment and reduce mortality after
hemorrhagic injury. This has the potential to fundamentally impact trauma care and patient
outcomes. Further work is indicated to assess the long-term risks associated with hemostatic
particle administration and further characterize their efficacy in large animal models where
the hemodynamic conditions of flow may have drastic effects on dosing and blood loss
outcomes.
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Nanoparticle Schematic and Characterization. a) Hemostatic nanoparticles (GRGDS-NPs)
consist of PLGA-PLL biodegradable polymer cores, with PEG arms that expose the GRGDS
moiety for targeting activated platelets. b) SEM shows nanoparticle size distribution and
morphology. c) 1H-NMR spectral analysis confirms the pegylation of the co-block-polymer
and the PEG-coronal structure of the nanoparticles. Deuterated water (top, gray overlay) and
deuterated chloroform (bottom, black overlay). d) These are administered intravenously via
the tail vein after a partial hepatectomy in the rat. The medial lobe (ML) is transected in this
model. Right (RL), left (LL) and caudate lobes (CL) are labeled for reference.
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Survival and Blood Loss. a-b) Survival is significantly increased by treatment with the
hemostatic GRGDS-functionalized nanoparticles. c-d) The liver mass is tightly controlled in
this injury model and is extremely reproducible in size, both in ratio to body mass (1.00% +/
− 0.13% S.D.) and in ratio to the remaining liver (22.8 %+/− 2.8% S.D.). The dotted lines on
the resected liver graph show the inclusion criteria for this study. e) There is a trend toward
a reduction in blood loss with the GRGDS-NP group, but is not significantly significant. f)
100% of animals with a blood volume loss less than 32% survive, but rapidly increases
above this threshold. Error bars represent SEM.
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Injury Surface Characterization. a) Hemostatic nanoparticles loaded with C6 (green) are
found integrated with the adherent clot after it is removed and examined under fluorescent
microscopy. b) The majority of bleeding appears to occur from the 2-4 major transected
blood vessels in this injury model. c) Scanning electron microscopy is used to verify the
presence of the nanoparticles (black arrow) and their integration with the fibrin mesh.
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Biodistribution. a) 31% of hemostatic GRGDS-NPs locate in the clot, versus 7% for the
scrambled-NP control group. Total mean nanoparticle recovery is 53.7% of total injected
dose for GRGDS and 29.6% for scrambled. b) The “Liver” group is representative of the
particle distribution to the uninjured lower left lobe of the liver. Minimal particle
distribution is found in the spleen and kidneys. Approx. 20% is found in the lungs for each
formulation. This may be indicative of microemboli in the lung or nanoparticles still in
pulmonary circulation.
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In vitro Testing. Outcomes include CT+CFT (a) and MCF (b). The GRGDS group had a
lower (faster) clotting time and a higher clot firmness compared to saline. Error bars
represent SEM. CT = Clotting Time; CFT = Clot Formation Time; MCF = Maximum Clot
Formation; CT+CFT is the sum total of the time it takes from initiation of the experiment
until a 20 mm clot is formed.
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